Open, multicenter clinical trial of nivolumab (BMS-936558) as monotherapy in subjects with advanced or metastatic squamous cell non-small cell lung cancer (NSCLC) who have received at least two previous lines of systemic treatment for the treatment of stage IIIb squamous cell NSCLC IV
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION (BMSIC)
- Phase: II
- Execution start: 08/04/2015
- End of execution: 30/05/2021
- IP: JAVIER VALDIVIA BAUTISTA